Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 5/20 | 0.51 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.50 |
| ▸ | EP300 | Q09472 | 5/20 | 0.34 |
| ▸ | POLA1 | P09884 | 1/20 | 0.31 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.30 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.30 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9569535 | 1.00 | FGFR1 (0.51) | FGFR1SLC22A6EP300POLA1PDE4D | |
| SCHEMBL9569545 | 1.00 | FGFR1 (0.51) | FGFR1SLC22A6EP300POLA1PDE4D | |
| SCHEMBL9569440 | 0.89 | FGFR1 (0.44) | FGFR1SLC22A6EP300POLA1 | |
| SCHEMBL9569433 | 0.89 | FGFR1 (0.44) | FGFR1SLC22A6EP300POLA1 | |
| SCHEMBL9569436 | 0.89 | FGFR1 (0.44) | FGFR1SLC22A6EP300POLA1 | |
| SCHEMBL9569641 | 0.87 | FGFR1 (0.47) | FGFR1SLC22A6EP300POLA1 | |
| SCHEMBL9569635 | 0.87 | FGFR1 (0.47) | FGFR1SLC22A6EP300POLA1 | |
| SCHEMBL9569629 | 0.87 | FGFR1 (0.47) | FGFR1SLC22A6EP300POLA1 | |
| SCHEMBL9569592 | 0.84 | FGFR1 (0.57) | FGFR1SLC22A6EP300POLA1PDE4D | |
| SCHEMBL9569603 | 0.84 | FGFR1 (0.57) | FGFR1SLC22A6EP300POLA1PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0532423-A1 | Novel unsaturated acyclic phosphonate derivatives of purine and pyrimidine | MERRELL DOW PHARMACEUTICALS INC. (US) | 1993-03-17 | — | — | EP | disclosed |